Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical outcomes of patients selected for RNA in situ hybridization for Thy-1. Table includes clinical outcomes data for patients with tissue analyzed by RNA ISH. PFS and OS are calculated from the completion date of adjuvant chemotherapy. Optimal surgery outcome is defined as residual disease < 1 cm. *** denotes that patient had no recurrence of disease

From: Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer